The Read Layer of the Stack
Illumina (ILMN) is the sequencing giant that sits underneath the Imperium pitch, even though it is not one of the promo’s picks. Adam O’Dell’s presentation builds a three-layer stack around DNA as software, and while the pitch itself centers on Twist Bioscience and Ginkgo Bioworks (DNA), Illumina is the company that makes the read layer possible. If Twist writes DNA and Ginkgo programs it, Illumina is the company that reads it at scale.
That read layer is the foundation the whole thesis rests on. Before anyone can design or write the code of living things, they need to read the existing code, and Illumina has been the dominant maker of DNA sequencers for years. Its machines are the workhorses of genomics, the ones that turn a sample into a long string of letters researchers can actually analyze.
Where Illumina Fits in O’Dell’s Framing
Illumina shows up in the Imperium pitch in two ways. It is named as a Twist Bioscience partner and customer, which makes sense: Twist makes synthetic DNA, and Illumina’s sequencers are often used to read and verify that DNA. Illumina is also one of the equipment-layer competitors the analysis names, alongside Thermo Fisher and Danaher.
The contrast with the promo’s picks is instructive. Twist and Ginkgo are cast as “over 600 times smaller than Nvidia” stories, small enough that the pitch can imagine a 600-times runway. Illumina is not that kind of story. It is an established large-cap that has already scaled, which is a different investment proposition entirely. That is not a knock on Illumina; it is simply a different risk profile.
What Illumina Actually Does
Illumina’s core business is sequencing, reading the order of the chemical letters in DNA. In plain terms, its machines take a biological sample and convert it into digital data, the same way a document scanner turns paper into text. That data then flows into every corner of the field: drug discovery, cancer diagnostics, agricultural genomics, and infectious-disease tracking.
The significance is that sequencing has become dramatically cheaper and faster over the last two decades, and Illumina has been at the center of that curve. That falling cost is part of why O’Dell’s thesis is even plausible. When reading DNA is cheap, the next step, writing and programming it, becomes a realistic business, which is exactly the layered argument the Imperium pitch is making.
Illumina Versus the Promo’s Picks
It is worth being clear about what this article is and is not. Illumina is a comparison name, a way to understand the field around the promo, not a name O’Dell is recommending in this presentation. The two picks at the center of Imperium are Twist Bioscience and Ginkgo Bioworks, and the apps layer is Absci.
For a deeper look at the names that are actually in the pitch, see our Twist Bioscience stock piece and our Ginkgo Bioworks stock piece. For the technology of reading DNA, our next-generation sequencing explainer covers the field in more detail.
O’Dell’s broader track record is worth remembering here. He teased Palantir in the $20s in spring 2024, and it became the best-performing stock in the S&P 500 for 2024, a real, checkable win. The Imperium pitch itself is a refreshed version of a theme he has run since 2021, with picks that have changed underneath it. Illumina’s role in all of this is steady and foundational: it is the company that reads the code the rest of the stack is built to write and run.
The Competitive Picture
Illumina competes at the equipment layer of the DNA field, and the competitive set is well established. Thermo Fisher and Danaher are the two other large tools names the Imperium analysis points to, and together the three represent the scaled end of the life-sciences tools market, the companies that already have the manufacturing, distribution, and customer relationships a young DNA startup has to build from scratch.
That contrast is the useful lens for reading the Imperium pitch. The promo is built around small, speculative names with big runways, the “over 600 times smaller than Nvidia” framing that invites investors to imagine a multi-hundred-fold outcome. Illumina is the other end of the spectrum: an established large-cap whose value is already reflected in a scaled business. Neither is inherently better; they are different bets for different investors. A reader who wants the theme without the microcap volatility will naturally look at the tools incumbents, while the pitch is aimed squarely at readers who want the maximum upside and are willing to accept the maximum risk.
That is the honest way to use Illumina in this conversation. It is the steady, scaled company that anchors the read layer, the name that makes the rest of the stack possible, and a useful reference point for understanding just how speculative the promo’s actual picks are.
Ready to see the research? Click here to access Adam O’Dell’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.